HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia.

Abstract
The source of CAR T cells can be autologous (autoCAR) or allogeneic (alloCAR). The latter is seen in patients with a history of allogeneic hematopoietic stem cell transplantation, and can be either donor-derived (DD-alloCAR) or recipient-derived (RD-alloCAR). While autoCAR is activated by CAR only, alloCAR receives activation signals from both T-cell receptor (TCR) and CAR. As a result, the biological differences could impact clinical outcomes. We retrospectively reviewed 31 patients: 17 received autoCAR, 11 received RD-alloCAR, and 3 received DD-alloCAR. After a median follow-up of 9 months, CR rate was 88.2% (95% CI 63.6-98.5%) in autoCAR and 100% (95% CI 71.5-100%) in RD-alloCAR. The median peak expansion in the autoCAR was significantly higher than the RD-alloCAR group (p = 0.007). RD-alloCAR group had significantly less patients with severe CRS (Grade ≥ 3) than the autoCAR group (p = 0.049). Acute graft-versus-host disease (GVHD) occurred in 2 (18.2%) of RD-alloCAR patients and 1 (33.3%) of DD-alloCAR patients. Univariate subgroup analysis of alloCAR group showed the presence of cGVHD at the time of T-cell collection was significantly associated with less than 6-month relapses (p = 0.022). RD-alloCAR patients with or without cGVHD at PBMC collection did not differ regarding the peak CAR T-cell expansion, CRS grades and OS.
AuthorsYongxian Hu, Jiasheng Wang, Guoqing Wei, Jian Yu, Yi Luo, Jimin Shi, Wenjun Wu, Kui Zhao, Lei Xiao, Yanlei Zhang, Zhao Wu, Huijun Xu, Alex Hongsheng Chang, He Huang
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 54 Issue 8 Pg. 1208-1217 (08 2019) ISSN: 1476-5365 [Electronic] England
PMID30518980 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, CD19
  • Receptors, Chimeric Antigen
Topics
  • Antigens, CD19 (immunology)
  • Female
  • Hematopoietic Stem Cell Transplantation (methods)
  • Humans
  • Male
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (genetics, pathology)
  • Receptors, Chimeric Antigen (metabolism)
  • Recurrence
  • Retrospective Studies
  • T-Lymphocytes (immunology)
  • Transplantation Conditioning (methods)
  • Transplantation, Homologous (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: